Composition for Preventing and/or Treating Metabolic Syndrome and Insulin Resistance Syndrome

A compound represented by the formula (2) or a salt or ester thereof.

A PPARγ ligand agent

• which comprises, as an active ingredient, at least one compound selected from among the compound represented by the formula (1), compounds represented by the formula (4) and compounds represented by the formula (5), or a salt or ester thereof:
• [In the above formulae, at least one of R1 to R4 is a prenyl group or at least one pair of neighboring two groups together represent —CH═CHC(CH3)2O— to form a six-membered ring and the others each independently represents H, OH, OCH3 or CHO. R5 and R6 each independently represents H, OH or OCH3. At least one of R7 and R8 is a prenyl group or R7 and R8 together represent —CH═CHC(CH3)2O— to form a six-membered ring;
• the other represents H, OH, OCH3 or CHO.]

A composition for the prevention and/or treatment of metabolic syndrome,

• which comprises, as an active ingredient, at least one compound selected from among the compound represented by the formula (1), compounds represented by the formula (4) and compounds represented by the formula (5), or a salt or ester thereof.
• [In the above formulae, at least one of R1 to R4 is a prenyl group or at least one pair of neighboring two groups together represent —CH═CHC(CH3)2O— to form a six-membered ring and the others each independently represents H, OH, OCH3 or CHO. R5 and R6 each independently represents H, OH or OCH3. At least one of R7 and R8 is a prenyl group or R7 and R8 together represent —CH═CHC(CH3)2O— to form a six-membered ring;
• the other represents H, OH, OCH3 or CHO.]

A composition for the prevention and/or treatment of insulin resistance syndrome,

• which comprises, as an active ingredient, at least one compound selected from among the compound represented by the formula (1), compounds represented by the formula (4) and compounds represented by the formula (5), or a salt or ester thereof
• [In the above formulae, at least one of R1 to R4 is a prenyl group or at least one pair of neighboring two groups together represent —CH═CHC(CH3)2O— to form a six-membered ring and the others each independently represents H, OH, OCH3 or CHO. R5 and R6 each independently represents H, OH or OCH3. At least one of R7 and R8 is a prenyl group or R7 and R8 together represent —CH═CHC(CH3)2O— to form a six-membered ring;
• the other represents H, OH, OCH3 or CHO.]

The composition according to 4

• which is to be eaten or drunk.

The composition according to 4

• which is used for medical or medicinal purposes.

The composition according to 4

• which is applied to domestic animals or pets.

A method for the prevention and/or treatment of metabolic syndrome,

• which comprises using at least one compound selected from among the compound represented by the formula (1), compounds represented by the formula (4) and compounds represented by the formula (5), or a salt or ester thereof:
• [In the above formulae, at least one of R1 to R4 is a prenyl group or at least one pair of neighboring two groups together represent —CH═CHC(CH3)2O— to form a six-membered ring and the others each independently represents H, OH, OCH3 or CHO. R5 and R6 each independently represents H, OH or OCH3. At least one of R7 and R8 is a prenyl group or R7 and R8 together represent —CH═CHC(CH3)2O— to form a six-membered ring;
• the other represents H, OH, OCH3 or CHO.]

A use of at least one compound selected from among the compound represented by the formula (1), compounds represented by the formula (4) and compounds represented by the formula (5), or a salt or ester thereof for the preparation of a composition for the prevention and/or treatment of metabolic syndrome:

• [In the above formulae, at least one of R1 to R4 is a prenyl group or at least one pair of neighboring two groups together represent —CH═CHC(CH3)2O— to form a six-membered ring and the others each independently represents H, OH, OCH3 or CHO. R5 and R6 each independently represents H, OH or OCH3. At least one of R7 and R8 is a prenyl group or R7 and R8 together represent —CH═CHC(CH3)2O— to form a six-membered ring;
• the other represents H, OH, OCH3 or CHO.]

A method for the prevention and/or treatment of insulin resistance syndrome,

• which comprises using at least one compound selected from among the compound represented by the formula (1), compounds represented by the formula (4) and compounds represented by the formula (5), or a salt or ester thereof:
• [In the above formulae, at least one of R1 to R4 is a prenyl group or at least one pair of neighboring two groups together represent —CH═CHC(CH3)2O— to form a six-membered ring and the others each independently represents H, OH, OCH3 or CHO. R5 and R6 each independently represents H, OH or OCH3. At least one of R7 and R8 is a prenyl group or R7 and R8 together represent —CH═CHC(CH3)2O— to form a six-membered ring;
• the other represents H, OH, OCH3 or CHO.]

A use of at least one compound selected from among the compound represented by the formula (1), compounds represented by the formula (4) and compounds represented by the formula (5), or a salt or ester thereof for the preparation of a composition for the prevention and/or treatment of insulin resistance syndrome:

• [In the above formulae, at least one of R1 to R4 is a prenyl group or at least one pair of neighboring two groups together represent —CH═CHC(CH3)2O— to form a six-membered ring and the others each independently represents H, OH, OCH3 or CHO. R5 and R6 each independently represents H, OH or OCH3. At least one of R7 and R8 is a prenyl group or R7 and R8 together represent —CH═CHC(CH3)2O— to form a six-membered ring;
• the other represents H, OH, OCH3 or CHO.]